Articles tagged with Glycoproteins
Researchers discovered Marburg virus enters human cells up to 300 times more efficiently than Ebola, thanks to its unique entry protein. A nanobody has been identified to block its attachment to the receptor, providing a potential therapeutic strategy.
Researchers at Northwestern University have discovered how pancreatic tumors evade the immune system and created an antibody therapy that blocks this mechanism, reawakening immune cells to attack cancer cells. The study shows promise for treating pancreatic cancer and may have broader implications for other hard-to-treat cancers.
Researchers identified hundreds of hidden binding partners for a blood protein receptor, revealing links to organ dysfunction and increased sepsis risk. The study found that Mrc1's absence led to the accumulation of mannosylated proteins, which disrupted normal physiology and function.
Researchers have made significant discoveries about the role of GP38 in viral infections and pathogenesis, highlighting its potential as a target for vaccines and medical countermeasures. Non-neutralizing GP38-specific antibodies have shown protective efficacy against lethal challenge, reducing circulating GP38 and vascular leak.
Researchers investigate the role of mucin's protein and glycan components in supporting Akkermansia muciniphila's growth. Native mucin and its O-glycans promote growth, while bovine milk N-glycans inhibit it.
A study characterizes the ubiquitination of Nrf1, a transcription factor, triggered by deglycosylating enzymes, leading to its inactivation and preventing it from functioning properly. This process is associated with proteasome dysfunction and age-related neurodegenerative diseases.
Researchers have discovered how a neutralizing antibody blocks measles virus infection by arresting the fusion process. The study's findings may also be relevant to other viruses with pandemic potential, such as Nipah and parainfluenza viruses.
Researchers have developed a novel approach to convert native sugars into diverse classes of stable glycosides and glycoproteins. This biomimetic concept uses 'cap and glycosylate' technology to selectively activate and substitute the anomeric hydroxyl group in a native sugar, generating a temporary thioglycoside intermediate that unde...
Researchers at Duke University have discovered a critical structure on the HIV virus that plays a crucial role in its infection process. By understanding this structure's dynamics, scientists may be able to design broadly neutralizing antibodies for an AIDS vaccine.
The Pirola variant of SARS-CoV-2 has rediscovered an entry pathway into lung cells that was previously used by earlier variants, which may promote the development of pneumonia. The virus uses the cellular enzyme TMPRSS2 for entry and is resistant to most therapeutic antibodies.
Researchers at Utrecht University have uncovered a sophisticated mechanism by which coronavirus spike proteins can be activated for cell entry. Sugar binding induces opening of the spike protein and exposure of the receptor binding domain, required for subsequent entry steps.
Scientists at Scripps Research have determined the structure of the critical protein complex that lets Lassa virus infect human cells, identifying new antibodies and vaccine targets. The research also found a high level of conservation across different lineages of the virus, paving the way for more effective vaccines and treatments.
Researchers from Rice University and Baylor College of Medicine are developing a new 'glyco-immune' checkpoint inhibitor to train the immune system to target and kill breast cancer metastasis in bones. The therapy has shown promise in preliminary tests, including eradicating cancer in some animals.
Researchers have developed a 'vein-on-a-chip' device that mimics the human vein, eliminating the need for animal models in some studies. The device, which includes structures called valves and endothelial cells, allows scientists to study mechanisms of blood clot formation in a realistic manner.
Researchers at La Jolla Institute for Immunology have developed a high-resolution view of the LCMV glycoprotein, revealing its structure and potential vulnerabilities. The breakthrough enables the development of an engineered antibody that can prevent LCMV disease, offering a new route to treatment.
A new study has deciphered a central regulatory mechanism of fibrin formation, proposing therapeutic approaches. Glycoprotein V controls thrombin activity and limits fibrin formation.
Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
Researchers at La Jolla Institute for Immunology have developed a new therapy for Lassa fever using a trio of rare human antibodies that can block viral infection. The therapy, called Arevirumab-3, was tested in non-human primates and proved 100% effective in treating the disease.
Scientists at the Francis Crick Institute developed a new method to study proteins released by cells, which could lead to tracking diseases like cancer. The Bio-Orthogonal Cell line-specific Tagging of Glycoproteins (BOCTAG) method identifies proteins uniquely made by diseased or cancerous cells, even in complex environments.
Researchers at ITQB NOVA and iMM discovered that the parainfluenza fusion peptide promotes membrane fusion by destabilizing the host's membrane and forming clusters of oligomeric structures. This breakthrough can contribute to developing antiviral therapies to prevent infection.
Scientists have discovered a new, high-resolution view of the rabies virus glycoprotein, which could lead to more effective vaccines. The study's findings suggest that a better-shaped vaccine could provide lifelong protection against the deadly disease.
Researchers at La Jolla Institute for Immunology have developed two human antibodies that target Ebola virus and Sudan virus, showing promise for a powerful antiviral therapy. The antibodies, 1C3 and 1C11, can block three glycoprotein sites on the virus at once and target the fusion machinery used by the viruses to infect host cells.
Researchers discover unique glycoprotein structure of Nipah and Hendra viruses, which could provide blueprint for vaccine design and antibody treatments. The findings suggest a multi-pronged approach to prevent and treat these deadly illnesses.
A study by Tokyo University of Science researchers identifies a novel regulatory axis targeting dendritic cell activity, suppressing autoimmune disease symptoms and bone loss. They discovered DCIR binds to glycoproteins on macrophages and osteoclasts, reducing inflammation and immune responses.
Researchers from Osaka University have demonstrated a rapid and robust chemical method for preparing highly pure glycoproteins. The new synthetic route uses an unprecedented amide bond formation reaction to form a junction between two functional peptides, resulting in a reliable means of synthesizing glycoproteins with little waste of ...
The study reveals that FBS2 protein is responsible for the lethality in NGLY1-knockout mice, causing cell growth suppression and accumulation of ubiquitinated glycoproteins. The absence of NGLY1 leads to proteasome inhibition, resulting in cell death.
The EuroPCR 2021 digital platform hosted 8,091 physicians from over 126 countries, offering a prime learning experience through real-time exchange and interactivity. The event featured 67 late-breaking trials, live chats, and practical Training Workshops, with 3-months access to the replayed Programme.
Researchers at the University of Illinois Chicago have discovered a second site on the filovirus glycoprotein that small drug molecules can bind to prevent infection. This finding holds promise for developing effective treatments for Ebola and Marburg viruses, which cause hemorrhagic fever with mortality rates ranging from 25% to 90%.
Researchers at Cornell University have engineered bacteria to produce glycoproteins, which are complex molecules attached to proteins. The goal is to create therapeutic reagents for cancer treatment and potentially develop a subunit vaccine against COVID-19.
Researchers at Nagoya City University develop a 10-amino acid sequence that enhances the cellular secretion of recombinant erythropoietin. The 'passport' sequence is recognized by a cargo receptor, allowing for improved production yields of biopharmaceuticals.
Researchers have designed efficient polymers to prevent ice growth and damage cells during cryo-storage. The study identifies key factors controlling the binding of flexible polymers to ice, paving the way for de novo design of more potent inhibitors.
Researchers have visualized a broadly neutralizing human monoclonal antibody, RVC20, which blocks the entry of the rabies virus into cells. The findings highlight new perspectives for prevention and treatment of the deadly disease.
Researchers at La Jolla Institute for Immunology identified the molecular properties of antibodies that neutralize Lassa virus. By understanding these properties, they can create a map for rational vaccine design, aiming to develop effective treatments or vaccines against this deadly disease.
A new pan-filovirus T-cell vaccine has been developed to protect against multiple filovirus species, including Ebola and Marburg. The vaccine induces killer T cells against conserved regions of inner filovirus proteins, offering potential protection against other known and unknown viruses in the filovirus family.
Researchers designed a quadrivalent fusion glycoprotein vaccine against human parainfluenza viruses, inducing up to 500-fold higher neutralizing immune responses. The shape-stabilized glycoproteins may offer a general class of vaccines against widespread parainfluenzas and related pathogens.
Researchers have developed a groundbreaking method for producing complex proteins, known as glycoproteins, in a cell-free system. This innovation has the potential to revolutionize personalized medicine by allowing for rapid and sustainable production of tailored protein medicines. The new approach uses a simplified reaction scheme tha...
Researchers at University of Akron discover the secret behind spider silk's sticky properties in humid conditions. They found that a combination of glycoproteins and low molecular mass compounds helps sequester interfacial water, preventing adhesive failure.
Researchers at Georgia Institute of Technology have developed a chemical trap that exhaustively catches trace glycoproteins, including those produced by cancer. This new method has proven effective in lab tests and could lead to early disease detection and targeted cancer treatments.
Researchers at Shinshu University used molecular simulations to understand the binding mechanism of antifreeze glycoproteins in polar fish. The study revealed that AFGPs can 'walk' on ice surfaces, selectively binding to growth points and preventing ice recrystallization.
Researchers at UC Santa Cruz have identified a promising route for designing an effective vaccine against respiratory syncytial virus (RSV). The study focused on the RSV G glycoprotein and found that protective antibodies target specific sites on the protein, which can induce an immune response.
Researchers at Argonne National Laboratory used X-ray crystallography to solve the structure of Lassa virus glycoprotein, a key component in vaccine development. The study provides valuable insights into how the virus enters human cells, paving the way for the design of an effective vaccine.
A team led by Kathryn Hastie and Erica Ollmann Saphire at The Scripps Research Institute has solved the structure of Lassa virus's surface glycoprotein, a key step in developing a vaccine. The breakthrough provides a blueprint to design a Lassa virus vaccine, which could help combat the deadly arenavirus family.
Researchers at Scripps Research Institute have designed a mimic of the viral protein from a different HIV subtype, subtype C, to combat many strains of HIV. The new immunogen was tested in non-human primates and showed promising results in eliciting neutralizing antibodies.
A viral protein in the chickenpox virus enhances its ability to hijack white blood cells and spread throughout the body. The protein interacts with chemokines to attract more white blood cells to the site of infection, allowing the virus to spread to other parts of the body.
Researchers from Hokkaido University conducted microgravity experiments on the International Space Station to measure ice crystal growth rates. They found that glycoproteins in fish blood facilitate growth, but also lead to a slowing effect when flat faces are truncated by slower-growing faces.
Scientists at TSRI have developed a method to analyze the glycan shield on HIV's protective outer glycoprotein, enabling the creation of a 'fingerprint' to identify potential vaccine targets. The new method saves time and has revealed that the glycoprotein does not have as many holes as previously predicted.
A Purdue University biochemist has created a protein array that can distinguish between glycoproteins, which are indicators of cancer and other diseases. The method, developed by W. Andy Tao, is 17-25 times more accurate than traditional testing procedures.
The BASKET-SAVAGE trial found that drug-eluting stents (DES) are more effective than bare metal stents (BMS) in treating saphenous vein grafts. DES reduced major adverse cardiac events by 67% compared to BMS.
Scientists at The Scripps Research Institute have solved the structure of a common virus's biological machinery, revealing important traits in Lassa virus. The research provides valuable insights into how to defend against its deadly cousin, Lassa fever, and may lead to the development of new treatments.
Researchers at UC Davis discovered that oligosaccharides, not protein compounds, are key to nourishing beneficial microbes in infants' guts. These findings suggest cow's milk could be used to create therapeutic prebiotics for infants.
Researchers have determined the near-atomic level map of Zika virus, showing a notable difference in one key surface protein compared to other flaviviruses like dengue. This structure may provide clues for understanding how Zika enters human cells and suggest ways to combat the virus with drugs or vaccines.
Researchers have isolated a collection of potent antibodies from an Ebola survivor that target the virus's glycoprotein stalk, providing significant post-exposure protection. These antibodies may lead to effective therapies to fight Ebola.
Researchers at Virginia Tech have developed a new adhesive material inspired by spider glue, with potential applications in creating environmentally non-toxic and energy-conserving products. The study revealed that ultraviolet rays play an important role in the performance of spider glue.
James Munro of Tufts University School of Medicine has received the NIH Director's New Innovator Award to develop a new way to use single molecule imaging of Ebola glycoproteins. This research aims to inform the design of structure-based vaccines to fight the spread of Ebola.
New studies at Johns Hopkins Medicine have made significant progress in developing a universally accurate diagnostic test for human herpes simplex viruses (HSV). Researchers also hope to create a vaccine that protects against the virus. The breakthrough is expected to improve screening tools, particularly in Africa where rates of HIV a...
Researchers developed a smart sensor chip that can detect subtle differences in glycoprotein molecules, improving prostate cancer diagnosis accuracy and reducing false positives. The technology focuses on the carbohydrate part of the molecule, which is essential for detecting disease.
Researchers have uncovered a key biological interaction that occurs during fertilization, identifying the protein in the zona pellucida that sperm latch onto. The study found that ZP2 is essential for sperm binding, and its absence leads to sterility in female mice.
Scientists at Princeton University discovered that herpes viruses may cause repetitive nerve cell firing, leading to persistent itching and pain. Understanding this mechanism could lead to improved treatments for shingles, oral, and genital herpes.
Scientists have made a breakthrough in understanding Respiratory Syncytial Virus (RSV) by identifying a highly vulnerable site on the virus's protein. The discovery provides new insights into how neutralizing antibodies work, which could lead to the development of more effective vaccines for infant respiratory illnesses.